ABCL vs. RNA, ADMA, ACLX, AKRO, RYTM, SRRK, IMVT, APLS, VKTX, and ACAD
Should you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include Avidity Biosciences (RNA), ADMA Biologics (ADMA), Arcellx (ACLX), Akero Therapeutics (AKRO), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Immunovant (IMVT), Apellis Pharmaceuticals (APLS), Viking Therapeutics (VKTX), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.
AbCellera Biologics vs.
AbCellera Biologics (NASDAQ:ABCL) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, community ranking, media sentiment, profitability, dividends, risk and institutional ownership.
61.4% of AbCellera Biologics shares are held by institutional investors. 28.0% of AbCellera Biologics shares are held by company insiders. Comparatively, 3.7% of Avidity Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
AbCellera Biologics has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
AbCellera Biologics presently has a consensus target price of $8.33, suggesting a potential upside of 166.67%. Avidity Biosciences has a consensus target price of $65.80, suggesting a potential upside of 102.99%. Given AbCellera Biologics' higher possible upside, equities research analysts plainly believe AbCellera Biologics is more favorable than Avidity Biosciences.
AbCellera Biologics has a net margin of -533.32% compared to Avidity Biosciences' net margin of -2,772.45%. AbCellera Biologics' return on equity of -15.73% beat Avidity Biosciences' return on equity.
Avidity Biosciences received 104 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 76.06% of users gave AbCellera Biologics an outperform vote while only 67.81% of users gave Avidity Biosciences an outperform vote.
In the previous week, AbCellera Biologics had 6 more articles in the media than Avidity Biosciences. MarketBeat recorded 9 mentions for AbCellera Biologics and 3 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.85 beat AbCellera Biologics' score of 0.64 indicating that Avidity Biosciences is being referred to more favorably in the news media.
AbCellera Biologics has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.
Summary
AbCellera Biologics beats Avidity Biosciences on 12 of the 18 factors compared between the two stocks.
Get AbCellera Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AbCellera Biologics Competitors List
Related Companies and Tools
This page (NASDAQ:ABCL) was last updated on 2/21/2025 by MarketBeat.com Staff
Free ABCL Stock Alerts